MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

被引：0

作者：

Yau, Christina ^{[1
]}

Wolf, Denise M. ^{[1
]}

Sanil, Ashish ^{[2
]}

Chien, Jo ^{[1
]}

Wallace, Anne ^{[3
]}

Boughey, Judy ^{[4
]}

Yee, Doug ^{[5
]}

Tripathy, Debu ^{[6
]}

DeMichele, Angela ^{[7
]}

Nanda, Rita ^{[8
]}

Chiu, Steven ^{[9
]}

Isaacs, Claudine ^{[10
]}

Albain, Kathy ^{[11
]}

Kaplan, Hank ^{[12
]}

Moulder, Stacey ^{[13
]}

Viscusi, Rebecca ^{[14
]}

Northfelt, Donald ^{[4
]}

Edmiston, Kirsten ^{[15
]}

Elias, Anthony ^{[16
]}

Styblo, Toncred ^{[17
]}

Haley, Barbara ^{[18
]}

Brown-Swigart, Lamorna ^{[1
]}

Flynn, Susan ^{[1
]}

Hirst, Gillian L. ^{[1
]}

Buxton, Meredith ^{[1
]}

Hylton, Nola ^{[1
]}

Paoloni, Melissa ^{[19
]}

Symmans, W. Fraser ^{[13
]}

Esserman, Laura ^{[1
]}

Berry, Don ^{[2
]}

Liu, Minetta C. ^{[4
]}

Park, John W. ^{[1
]}

van 't Veer, Laura ^{[1
]}

机构：

[1] Univ Calif, Davis, CA USA

[2] Berry Consultants LLC, Austin, TX USA

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Mayo Clin, Rochester, MN USA

[5] Univ Minnesota, Minneapolis, MN 55455 USA

[6] Univ So Calif, Los Angeles, CA 90089 USA

[7] Univ Penn, Philadelphia, PA 19104 USA

[8] Univ Chicago, Chicago, IL 60637 USA

[9] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[10] Georgetown Univ, Washington, DC 20057 USA

[11] Loyola Univ Med Ctr, Maywood, IL 60153 USA

[12] Swedish Canc Inst, Seattle, WA USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[14] Univ Arizona, Tucson, AZ 85721 USA

[15] Inova Hlth Syst, Ames, IA USA

[16] Univ Colorado, Boulder, CO 80309 USA

[17] Emory Univ, Atlanta, GA 30322 USA

[18] Univ Texas, Houston, TX USA

[19] Quantum Leap Healthcare, Los Angeles, CA USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-06-29

引用

页数：2

共 50 条

[41] Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Yau, Christina
Wolf, Denise
Brown-Swigart, Lamorna
Hirst, Gillian
Sanil, Ashish
Singhrao, Ruby
Asare, Smita
DeMichele, Angela
Berry, Don
Esserman, Laura
van 't Veer, Laura
Nanda, Rita
Liu, Minetta
Yee, Douglas
[J]. CANCER RESEARCH, 2018, 78 (04)
[42] Operational standardization and quality assurance yield high acceptance rate for breast MRI in the I-SPY 2 TRIAL
Gibbs, Jessica
Newitt, David C.
Watkins, Margarita
Li, Wen
Cimino, Lisa
Li, Clifton
Onishi, Natsuko
Wilmes, Lisa J.
Bareng, Teffany Joy
Proctor, Evelyn
LeStage, Barbara
Parker, Bev
Hylton, Nola M.
[J]. CANCER RESEARCH, 2021, 81 (04)
[43] Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Schwab, Richard
Clark, Amy S.
Yau, Christina
Hylton, Nola
Li, Wen
Wolfe, Denise
Chien, A. Jo
Wallace, Anne M.
Forero-Torres, Andres
Stringer-Reasor, Erica
Nanda, Rita
Jaskowiak, Nora
Boughey, Judy
Haddad, Tufia
Han, Heather S.
Lee, Catherine
Albain, Kathy
Isaacs, Claudine
Elias, Anthony D.
Ellis, Erin D.
Shah, Payal
Lang, Julie E.
Lu, Janice
Tripathy, Debasish
Kemmer, Kathleen
Yee, Douglas
Haley, Barbara
Majure, Melanie
Roesch, Erin
Vaklavas, Christos
Ewing, Cheryl
Helsten, Teresa
Symmans, W. Fraser
Perlmutter, Jane
Rugo, Hope S.
Melisko, Michelle
Wilson, Amy
Singhrao, Ruby
van't Veer, Laura
De Michele, Angela
Asare, Smita
Berry, Don
Esserman, Laura J.
[J]. CANCER RESEARCH, 2019, 79 (13)
[44] DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Glas, Annuska
Petricoin, Emanuel
Wulfkuhle, Julia
Severson, Tesa M.
Linn, Sabine
Brown-Swigart, Lamorna
Hirst, Gillian
Buxton, Meredith
DeMichele, Angela
Hylton, Nola
Symmans, Fraser
Yee, Doug
Paoloni, Melissa
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo
van t'Veer, Laura
[J]. NPJ BREAST CANCER, 2017, 3
[45] DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Denise M. Wolf
Christina Yau
Ashish Sanil
Annuska Glas
Emanuel Petricoin
Julia Wulfkuhle
Tesa M. Severson
Sabine Linn
Lamorna Brown-Swigart
Gillian Hirst
Meredith Buxton
Angela DeMichele
Nola Hylton
Fraser Symmans
Doug Yee
Melissa Paoloni
Laura Esserman
Don Berry
Hope Rugo
Olufunmilayo Olopade
Laura van ‘t Veer
[J]. npj Breast Cancer, 3
[46] Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Yeung, Kay T.
Kalinsky, Kevin
Yau, Christina
Chien, Amy Jo
Boughey, Judy Caroline
Stringer-Reasor, Erica Michelle
Falkson, Carla Isadora
Albain, Kathy S.
Mayer, Ingrid A.
Trivedi, Meghna S.
Nanda, Rita
Douglas, Emily H.
Omene, Coral Oghenerukevwe
Rugo, Hope S.
Isaacs, Claudine
Parker, Beverly
DeMichele, Angela
Yee, Douglas
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA520 - LBA520
[47] Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A.
Roesch, Erin
Yau, Christina
Lu, Ruixiao
Wolf, Denise
Samson, Susan
Stafford, Debra
Albain, Kathy S.
Isaacs, Claudine
Trivedi, Meghana
Yee, Douglas
Boughey, Judy
Thomas, Alexandra
Chien, A. Jo
Hylton, Nola
Li, Wen
DeMichele, Angela
Perlmutter, Jane
Symmans, W. Fraser
Hershman, Dawn L.
Melisko, Michelle
Veer, Laura J. van ' t
Wilson, Amy
Asare, Smita M.
Berry, Donald A.
Schwab, Richard
Rugo, Hope S.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2022, 82 (04)
[48] Efficacy of T-DM1+pertuzumab over standard therapy for HER2+breast cancer: Results from the neoadjuvant I -SPY 2 TRIAL
DeMichele, Angela M.
Moulder, Stacy
Buxton, Meredith
Yee, Douglas
Wallace, Anne
Chien, Jo
Isaacs, Claudine
Albain, Kathy
Boughey, Judy
Kemmer, Kathleen
Haley, Barbara
Lang, Julie
Kaplan, Henry
Minton, Susan
Forero, Andres
Elias, Anthony
Nanda, Rita
Korde, Larissa
Schwab, Richard
Melisko, Michelle
Sanil, Ashish
Hogarth, Michael
Hylton, Nola
Paoloni, Melissa
Symmans, Fraser
Perlmutter, Jane
Lyandres, Julia
Yau, Christina
Berry, Don
Esserman, Laura
[J]. CANCER RESEARCH, 2016, 76
[49] Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Isaacs, Claudine
Nanda, Rita
Chien, Jo
Trivedi, Meghna S.
Stringer-Reasor, Erica
Vaklavas, Christos
Boughey, Judy C.
Sanford, Amy
Wallace, Anne
Clark, Amy S.
Thomas, Alexandra
Albain, Kathy S.
Kennedy, Laura C.
Sanft, Tara B.
Kalinsky, Kevin
Han, Hyo S.
Williams, Nicole
Arora, Mili
Elias, Anthony
Falkson, Carla
Asare, Smita
Lu, Ruixiao
Pitsouni, Maria
Wilson, Amy
Perlmutter, Jane
Rugo, Hope
Schwab, Richard
Symmans, W. Fraser
Hylton, Nola M.
Van't Veer, Laura
Yee, Douglas
DeMichele, Angela
Berry, Donald
Esserman, Laura J.
[J]. CANCER RESEARCH, 2023, 83 (05)
[50] PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Stringer-Reasor, Erica
Shatsky, Rebecca A.
Chien, Jo
Wallace, Anne
Boughey, Judy C.
Albain, Kathy S.
Han, Hyo S.
Nanda, Rita
Isaacs, Claudine
Kalinsky, Kevin
Mitri, Zahi
Clark, Amy S.
Vaklavas, Christos
Thomas, Alexandra
Trivedi, Meghna S.
Lu, Janice
Asare, Smita
Lu, Ruixiao
Pitsouni, Maria
Wilson, Amy
Perlmutter, Jane
Rugo, Hope
Schwab, Richard
Symmans, W. Fraser
Hylton, Nola M.
Van 't Veer, Laura
Yee, Douglas
DeMichele, Angela
Berry, Donald
Esserman, Laura J.
[J]. CANCER RESEARCH, 2023, 83 (05)

← 1 2 3 4 5 →